checkedPsychopharmacology and Psychiatry Updates2026-11-08last verified 2026-11-08

did a european psychiatry review find antipsychotics helped catatonia in 60% of trials and harmed in 10%?

verdict: confirmed
the primary source says it, at that magnitude
“The main finding of the review is that antipsychotics were useful for catatonia in 60% of trials, but harmful in 10%.”

a guest, Dr. Scott Beach (psychiatrist presenting the review) said on Psychopharmacology and Psychiatry Updates, 2026-11-08, at 06:05. hear it in context → the speaker cited: a recent systematic review in European Psychiatry.

the episode: Catatonia: Should Antipsychotics Always Be Avoided? (at 06:05). we link the show's own page; we do not re-host audio.

first, the part that holds

the numbers are right. a 2025 systematic review in european psychiatry found antipsychotic use was judged beneficial in 60.0% of 175 treatment episodes and harmful in 10.9%, and the speaker's "10%" is that figure rounded down slightly.

what we found when we went and looked

we read the review, "the use of antipsychotics in the treatment of catatonia: a systematic review" (european psychiatry, 2025, 68(1):e48), on the publisher's site and on pubmed central. its abstract says antipsychotic use "was considered beneficial in 60.0% of the trials, neutral in 29.1%, and harmful in 10.9%". that is 105, 51 and 19 of 175 antipsychotic trials in 110 patients, drawn from 79 articles. one thing to know when you hear the word "trials": in this review a trial means one patient starting an antipsychotic or changing its dose after catatonia began. 148 of the 175 came from 77 published case reports, and only one open-label clinical study was included, so none of these were randomized controlled trials.

assertion by assertion

assertionverdictwhat the record says
the review found antipsychotics were useful (beneficial) for catatonia in 60% of trialsconfirmedabstract: "beneficial in 60.0% of the trials" (105 of 175). beneficial meant improvement or complete recovery, as judged from the published reports. [1][2][3]
the review found antipsychotics were harmful in 10% of trialsconfirmedabstract: "harmful in 10.9%" (19 of 175). this covered worsening, malignant catatonia, neuroleptic malignant syndrome or death. the authors report neuroleptic malignant syndrome in four patients and three deaths. 10% is a slight round-down of 10.9%. [1][2][3]
the source is a recent systematic review in european psychiatryconfirmedpublished online 24 march 2025 in european psychiatry, 68(1):e48, doi 10.1192/j.eurpsy.2025.9. it followed prisma guidelines and searched medline and web of science for 2000-2023. [1][3]
the popular reading that the 'trials' were controlled clinical trialsfalsein this review a 'trial' is one patient starting an antipsychotic or changing its dose after catatonia began. 148 of the 175 came from 77 case reports. only one open-label clinical study (15 patients) was included, and there were no randomized trials. [1][2][3]
the remaining 30% were neutral, not harmfulconfirmed29.1% of trials (51 of 175) were neutral. the authors say that with few exceptions they found non-beneficial outcomes for all second-generation antipsychotics, in varying proportions. [1][3]

both directions

for the speaker: the review's abstract and its results counts (105 beneficial, 51 neutral, 19 detrimental out of 175) match both figures the speaker gave, and the speaker named the journal correctly. the authors' own conclusion, "antipsychotics could be an option in the treatment of catatonia in psychotic patients", is in line with how the speaker framed the review. psychotic disorders were the underlying cause in 65.8% of cases.

against: the percentages describe published case reports, not a representative sample of patients. the authors write that almost all of the data come from case reports, which are "subject to various biases, such as publication bias, recall bias, and overinterpretation". they also say that "adverse outcomes with newer drugs may be under-reported", so the true harm rate could be higher than 10.9%. results varied a lot by drug. outcomes were mostly reported as beneficial for amisulpride, clozapine and risperidone, mixed for aripiprazole and olanzapine, and mostly detrimental for haloperidol and quetiapine. 14 of the 19 harmful trials involved first-generation antipsychotics. benzodiazepines were co-prescribed in 36.6% of trials, which muddies attribution. only 41.1% of patients had tried a benzodiazepine before the antipsychotic.

what this cannot say

the review cannot give a real efficacy or harm rate, because there is no control group or denominator of all treated patients, and the outcome labels were assigned qualitatively from case-report narratives. the authors themselves say comparisons between groups are limited by inconsistent reporting. we checked only the published review. we did not re-extract the 79 underlying articles, and we did not hear the episode beyond the quoted sentence. the pubmed abstract page would not load for us, so we used the pubmed central full text and the publisher's pages.

the medication pages behind this check

sources, each one fetched and read

  1. The use of antipsychotics in the treatment of catatonia: a systematic review. European Psychiatry, 2025;68(1):e48. doi:10.1192/j.eurpsy.2025.9 (publisher abstract page) What we read there: "Among them, we identified 175 antipsychotic trials (in 110 patients)... Antipsychotic use was considered beneficial in 60.0% of the trials, neutral in 29.1%, and harmful in 10.9%." Fetched 2026-11-08 (HTTP 200). https://www.cambridge.org/core/product/332FE3F1201E16C3F67ECBB059DA85DD
  2. The use of antipsychotics in the treatment of catatonia: a systematic review. European Psychiatry, 2025;68(1):e48 (full text, Cambridge Core reader) What we read there: "Almost all of the included data come from case reports, which are primarily written to report unusual events and are subject to various biases, such as publication bias, recall bias, and overinterpretation." NMS occurred in four patients; three patients died; BZD co-prescribed in 64 trials (36.6%). Fetched 2026-11-08 (HTTP 200). https://www.cambridge.org/core/product/332FE3F1201E16C3F67ECBB059DA85DD/core-reader
  3. The use of antipsychotics in the treatment of catatonia: a systematic review. European Psychiatry, 2025;68(1):e48. PMC12041727 (PubMed ID 40123412) What we read there: Beneficial 105, neutral 51, detrimental 19 of 175 trials in 110 patients; 148 trials from 77 case reports and one open-label study of 15 patients; published 24 March 2025. Fetched 2026-11-08 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC12041727/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam